anti-TP53 R175H/HLA-A 02:01 TCR T-cell therapy (Affini-T Therapeutics)

N/A

Report date: 2025/06/11 10:49:30

Base Information

Drug Nameanti-TP53 R175H/HLA-A 02:01 TCR T-cell therapy (Affini-T Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulators +[5] 
TargetsHistocompatibility antigens class IITumor protein p53HLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAffini-T Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAffini-T Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A